Figure 2.

Least squares mean changes in TSQM global treatment satisfaction by a subgroup of most recent prior disease-modifying therapy. Prior therapies were (a) natalizumab; (b) teriflunomide, dimethyl fumarate, fingolimod, or siponimod; or (c) IFN-β-1a, IFN-β-1b, pegylated IFN-β-1a, or glatiramer acetate (MMRM analysis). The TSQM version 1.4 scale is 0-100. One patient was excluded from the MMRM analysis because methylprednisolone was incorrectly recorded in the electronic case report form as a prior DMT. LS mean changes are estimated from mixed effects models with study visit as the time axis with adjustment for baseline scores; an unstructured correlation matrix was used to model within-person correlations.

BL: baseline; EOS: end of study; M: month; TSQM: Treatment Satisfaction Questionnaire for Medication; IFN: interferon; MMRM: mixed-effect model for repeated measures; DMT: disease-modifying therapy; LS: least square.